

Cannabis Consumption Lounge Opt In / Out Information

**Presented by
Crislove Igeleke, Deputy City Attorney
And
Darcy Adelbai-Hurd, Business Licensing Manager**

Submitted at Meeting
Date: 9/21/22 Item 37
By Staff





September 1, 2022-Opt In Letter received from Cannabis Compliance Board (CCB)

- Due: September 9, 2022
- No response = automatically opted “IN.”


Response Form For The City of Las Vegas For The CCB’s 2022 Cannabis Consumption Lounge Licensing Round

It is the intent of The City of Las Vegas that, regarding the 2022 cannabis consumption lounge licensing round **only**:

- it **will not** issue cannabis consumption lounge business licenses in its jurisdiction based on either the provisions in the Las Vegas Municipal Code as of the date this form was executed and/or any future amendments or revisions to the Las Vegas Municipal Code.
- it **will** issue cannabis consumption lounge business licenses in its jurisdiction, and the Las Vegas Municipal Code will be amended or revised to reflect that intent.

This form reflects The City of Las Vegas’s intent to participate or opt out of the Cannabis Compliance Board’s (the “CCB”) 2022 cannabis consumption lounge licensing round **only**. This form will not bind nor exclude The City of Las Vegas as a participating jurisdiction in any future cannabis establishment licensing rounds held by the CCB.





- At the September 7th, City Council meeting hearing item to discuss the council position added.
- Each applicant **MUST** apply for a **license** and **special use permit** and obtain **City Council approval** to operate within our jurisdiction.
- City of Henderson, City Of North Las Vegas, and Boulder City have all **opted out**.
- Clark County and City of Las Vegas have **opted in**.
- The map depicts where independent lounges may be situated within the City limits.





City of Las Vegas CANNABIS CONSUMPTION LOUNGE DRAFT

-  DISPENSARY
-  CULTIVATION
-  PRODUCTION
-  TESTING LABORATORY

-  Protected Used Buffers
-  C-1 - Limited Commercial
-  C-2 - General Commercial
-  C-M - Commercial/Industrial
-  M - Industrial
-  Fremont

Prohibited Areas

-  Fremont
-  300' From Protected Uses
-  1000' From Schools and Cannabis Dispensary
-  1500' From Nonrestricted Gaming Establishments



Turn scan
PDFs with

Printed: 8/27/2021 11:27:07 AM

All maps are created, produced
and printed by the City of Las Vegas
Department of Information Systems
Geographic Information System
Planning & Development Dept.
702.258.8001





- **Consumption Lounge Ordinance = Social Use Venue**
 - In 2019, CLV passed an ordinance for SUV
 - In 2021, AB 341 passed: STATEWIDE legislation
 - Retail Cannabis Stores owners may only apply for 1 Lounge
 - CLV has 17/22 licensed Retail Cannabis Stores currently
 - The state estimates 40-45 retail (attached) lounges across the state
 - 20 Independent Lounges (STATEWIDE) – detached will have to have a different business model to be sustainable.
 - 10 of those are designated for Social Equity Applicants





Next Steps (if opting in):

1. State: Application period opens: October 14, 2022, 8:00 a.m.
Application period closes: October 27, 2022, 5:00 p.m.
2. CLV: Amend LVMC 6.96 (Social Use Venues) to merge to LVMC 6.95 Cannabis Establishments
3. BIS: A new ordinance to the Business Community – to include Consumption Lounges
4. Timeline: Potential adoption of a Consumption Lounge ordinance Jan/Feb '23. Accepting applications then. Council has SUP and BL to consider approvals for each location.



QUESTIONS?



MEMO

To: Division of Public Health (DPBH)
From: Anansi Enterprise LLC – (Tim Eli Addo & Kofi Forkuo-Sekyere)
Date: June, 6, 2020
Re: Recall Procedures for Cannabis in Nevada

Nevada should be proactive in its approach for strengthening recall procedures for contaminated cannabis products. Increasing strength of lab testing is an important step for guaranteeing consumer safety. However, stronger testing needs to be paired with ways for warning the public of contaminated cannabis products. Establishing an effective cannabis recall program now will help ensure Nevada's gaming industry can safely create revenue share models for cannabis. The gaming and tourism industries will seek to profit from another potential lucrative revenue stream as cannabis get closer to federal legalization. **Anansi Enterprise is prepared to provide recall procedures for each step of the cannabis supply chain (sellers, producers, distributors, testing facilities).**

Submitted at City Council

Date 9/21/22 Item 37

By: Timothy Eli Addo

Policy Issue: The current method the Department of Taxation uses to notify the public of recall is ineffective in notifying all the parties involved. The lack of notification to affected parties can be fatal, especially since medicinal cannabis patients may already suffer from a compromised immune system. Nevada needs to be equipped with a method of notification and containment for potential recalls on cannabis products.

Public safety should be the highest priority for cannabis regulators

This memo is not written in fear that an issue may happen. Fatalities from contaminated cannabis have already happened in two states. Although, it had limited press coverage, the deaths still leave a lasting impact. This issue affects the consumers, and also the cultivators, processors, and dispensaries that may be liable. **Given the current pandemic, producers and sellers are more prone to contamination since they are experiencing a surplus in inventory; forcing companies to find new, unproven, ways to store cannabis safely.**

Moreover, contaminants in cannabis products can be a tremendous burden for medical patients waiting to receive an organ transplant. The American Association for the Studies of Liver Diseases (AASLD) has warned potential recipients to refrain from using cannabis because containments can have fatal effects on the transplant procedures. Better testing and recall procedures will help hopeful transfer recipients to consume cannabis for medicinal purposes.

- Other consumer goods are subject to Federal and State product recall procedures. These procedures try to increase the probability of notification and recapturing of affected products
 - The FDA requires the following for recall strategies:
 - Classification of recall (in terms of severity)
 - Public Warning
 - Effectiveness Check Level (ensuring all parties who sold and consumed products have been notified)
- Solidifying Nevada's recall program will further legitimize the state's cannabis programs by providing assurance to consumers
 - Consumers will have proper notification if a contaminant issue ever occurs
 - Other states will look to Nevada's improved recall procedures as a blueprint to enact similar procedures in their state
- Preventative measures need to be placed to ensure fatalities will not happen again as a result of neglect from regulators
 - Fatalities from contaminants have already occurred in the cannabis industry. In both cases, the products in question had received a passing grade from the lab.
 - Collection of new data sources are not needed to enact a safe recall protocol. The cannabis industry is already stringent. The amount of personal information required for all parties involved, especially the consumers, is already known and written into law. This information can be leveraged to provide an affective recall tool, that the state and MME's can access.

Solution: Ensure implementation of proper recall procedures for every licensed cannabis facility in Nevada. This includes establishing protocols for each facility and employee that could be involved with a product recall, especially compliance managers and directors. Recall procedures will include a technology application that tracks information about the cannabis product; including, the location of the batch to provide a current map of batch location. Templates will be provided for companies and employees who wish to conduct a voluntary recall. This solution will make sure that all parties involved – including the end user – are properly notified.

The solution we offer considers the following as criteria for solving this urgent public health issue:

1. Notifying the public and affected parties in an urgent manner
2. Training of all personnel involved with product recalls
3. Isolating the entities affected to stop a faulty product from spreading
4. Providing accurate mapping of batch distribution, including times of distribution
5. Making participation mandatory for all MMEs (dispensaries)
6. Accessibility by all registered cannabis companies in the State of Nevada

Implementation: Implementation of solution will require training all licensed cannabis facilities on the steps of conducting an effective recall. Relevant personnel will learn the steps one should take in the event of a recall. This includes training personnel on how to complete templates when conducting a voluntary recall. A bi-weekly import of information is required from dispensaries, cultivators, and processors to help map the distribution of batches. This information is currently being logged in various systems by employees and can be reviewed by the state for medicinal patients. This process only requires data that is already required for submission by cannabis entities to be compliant with Nevada Law.

Information needed includes:

- Name and/or zip code of customer who purchased batch
- Time of purchase
- Method of contact (phone, email, social media, etc....)

About Anansi Enterprise LLC

Anansi Enterprise is founded by Tim Eli Addo. Eli continues to be an inspiring voice for patient advocacy and minority involvement in the Nevada Cannabis industry. A brilliant mind, Eli plays an important role in Nevada's patient advocacy through current hemp and cannabis legislation. In 2013, Eli was one of the pioneers behind the hemp industry in Nevada. He lobbied House of Representatives Congresswoman Dina Titus (d) and former Congressman Joe Heck (r) to cosponsor the HR 525 Farm Bill. Also, Eli was instrumental in drafting the language for important amendments to SB 374, two of which further patient advocacy: the ability for patients to test their cannabis products at a state licensed Nevada testing lab. Furthermore, Eli helped establish the foundation for the cannabis market in Nevada through operational consulting for MMEs as a R&D consultant for Cannalysis, which includes consultation on anything from the production,

testing and compliance. *Eli continues to fight for minority representation in the Nevada cannabis industry, especially when it comes to cannabis legislation. Nevada is filled with smart people who can greatly impact cannabis and cannabis legislation. Unfortunately, because many of these people are minorities, Nevada – and other states – have not yet capitalized on this opportunity. Therefore, Anansi Enterprise seeks to provide diverse and effective leadership regarding cannabis legislation.*

For more information about Anansi Enterprise visit <https://anansi.io>

To read more about Eli's inspirational story, click the links below:

<https://invisibleproject.org/timothy-eli-addo/>

<https://uspainfoundation.org/news/pain-warrior-month-timothy-eli-addo/>

PATIENT SAMPLE ONLY - NOT FOR RESALE

(702) 209-2429

info@digipathlabs.com

6450 Cameron St. #113 Las Vegas, NV 89118



MME: Scott Lacombe
MME ID: P090401422

Sample ID: F20161121-05-1

Report Date: 11/23/2016

Batch/Lot #: N/A

Name: Land Race
Sample Type: Flower

Potency Test Results

| | | | |
|---------------------------|---------|--------------|---------|
| THCA | 3.8 % | d9THC | 0.261 % |
| CBDA | 0.000 % | CBD | 0.000 % |
| Total Cannabinoids | | 4.1 % | |

| Cannabinoid | % mass | mg/g |
|---------------|--------|-------|
| CBC | 0.030 | 0.300 |
| CBD | 0.000 | 0.000 |
| CBDA | 0.000 | 0.000 |
| CBDV | 0.000 | 0.000 |
| CBG | 0.001 | 0.010 |
| CBGA | 0.014 | 0.140 |
| CBN | 0.000 | 0.000 |
| Δ 9THC | 0.261 | 2.610 |
| Δ 8THC | 0.000 | 0.000 |
| THCV | 0.054 | 0.540 |
| THCA | 3.8 | 37.57 |

| | |
|--------------------------------|---------|
| Potential Total Δ 9THC* | 3.556 % |
| Potential Total CBD* | 0.000 % |

*Decarboxylation of the acidic form to the neutral form accounts for the potential values above

| Terpenoid | % mass | mg/g |
|------------------------|--------|-------|
| α -bisabolol | 0.000 | 0.000 |
| α -humulene | 0.026 | 0.255 |
| α -pinene | 0.319 | 3.195 |
| α -terpinene | 0.000 | 0.001 |
| β -caryophyllene | 0.028 | 0.280 |
| β -myrcene | 0.051 | 0.515 |
| β -pinene | 0.062 | 0.617 |
| camphene | 0.004 | 0.041 |
| caryophyllene oxide | 0.001 | 0.008 |
| delta-3-carene | 0.000 | 0.004 |
| gamma-terpinene | 0.000 | 0.002 |
| geraniol | 0.000 | 0.000 |
| guaiol | 0.000 | 0.000 |
| isopulegol | 0.000 | 0.002 |
| limonene | 0.016 | 0.160 |
| linalool | 0.000 | 0.002 |
| trans nerolidol | 0.001 | 0.011 |
| ocimene | 0.013 | 0.126 |
| p-cymene | 0.000 | 0.000 |
| eucalyptol | 0.000 | 0.000 |
| terpinolene | 0.000 | 0.002 |

Safety & Quality Tests

| | |
|-------------------|------------|
| Visual | Pass |
| Heavy Metals | Not Tested |
| Pesticides | Not Tested |
| Residual Solvents | Not Tested |
| Microbiological | Not Tested |
| Mycotoxins | Not Tested |
| Moisture Content | % |

Scan to View Results at DigiPathLabs.com



NEVADA LABEL REQUIREMENTS

| | | | |
|---------------|---------|-----|---------|
| Δ 9THC | 0.261 % | CBD | 0.000 % |
| THCa | 3.8 % | CBN | 0.000 % |

I certify that this sample has been tested by DigiPath Labs. All results are reported on AS-IS basis.

DigiPath Lab Manager Signature:

PATIENT SAMPLE ONLY - NOT FOR RESALE



CHEMOVAR.IO

TIM ELI ADDO | EMAIL:ELI@CANALYSISLAB.COM

THC Cap Passes in House

Recently, the Florida House passed a THC Cap, limiting the potency of cannabis products to 10% for medical patients under the age of 21. Many opponents of this amendment fear that product availability will suffer. This especially concerning for moms with children who have a chronic illness. These moms are uncertain if cannabis products will potent for their children.

THIS ARTICLE IS TO REASSURE PEOPLE WHO ARE WORRIED A THC CAP WILL IMPEDE THE PROGRESS OF THE CANNABIS INDUSTRY. There exist viable genetics for cannabis plants that are low in THC potency yet will provide more medicinal benefits than most products that currently exist in the cannabis market. These low THC chemovars make use of other cannabinoids like THCV.

Topics

1. *How prohibition created the THC craze*
2. *Essential cannabinoids and terpenes that produce an entourage effect. These cannabinoids and terpenes are being tested for treating a wide range of diseases and injuries*
3. *Research on chemovars that will expand clinical trials and academic research of the medicinal benefits of cannabis*

Why are products potent in THC?

THC is considered to be the main cannabinoid responsible for the psychoactive effect of cannabis. THC can be found in most cannabis products, including flower, vape cartridges, oils, tincture, and edibles. The average THC for cannabis products has been increasing every year. It's common to find flower with potency levels of 20-30% THC, vape cartridges can have 70-99% THC.

Cannabis has longed been plagued by prohibition. There are severe punishments for being caught with cannabis. Cannabis producers overtime became astute at generating more THC in their cannabis stock. Producers did this so that they can generate smaller yields and decrease their chances of being caught by law enforcement.

Gradually, consumers could buy less cannabis because the THC potency became more concentrated. Cannabis prohibition helped create a trend of products that have high THC potency, as alcohol prohibition help expand the liquor industry to generate products with higher alcohol content

“Cannabis prohibition helped create a trend of products that have high THC potency”

PATIENT SAMPLE ONLY - NOT FOR RESALE

702.209.2429 info@digiPathLabs.com 6450 Cameron St #111 Las Vegas, NV 89118

CERTIFICATE

 MME: Scott Lacombe
MME ID: P090401422

Sample ID: F20161121-05-1
Report Date: 11/23/2016
Batch/Lot #: N/A

Name: Land Race
Sample Type: Flower

Potency Test Results

| THCA | 3.8 % | Δ9THC | 0.261 % |
|---------------------------|---------|--------------|---------|
| CBDA | 0.000 % | CBD | 0.000 % |
| Total Cannabinoids | | 4.1 % | |

| Cannabinoid | % mass | mg/g |
|-------------|--------|-------|
| CBC | 0.039 | 0.300 |
| CBD | 0.000 | 0.000 |
| CBDA | 0.000 | 0.000 |
| CBV | 0.000 | 0.000 |
| CBG | 0.001 | 0.010 |
| CBGA | 0.014 | 0.140 |
| CBN | 0.000 | 0.000 |
| Δ9THC | 0.261 | 2.610 |
| Δ8THC | 0.000 | 0.000 |
| THCV | 0.054 | 0.540 |
| THCA | 3.8 | 37.57 |

Potential Total Δ8THC* 3.556 %
Potential Total CBD* 0.000 %

*Decarboxylation of the acidic form to the neutral form accounts for the potential values above

Safety & Quality Tests

| | |
|-------------------|------------|
| Visual | Pass |
| Heavy Metals | Not Tested |
| Pesticides | Not Tested |
| Residual Solvents | Not Tested |
| Microbiological | Not Tested |
| Mycotoxins | Not Tested |
| Moisture Content | % |

Scan to View Results at DigiPathLabs.com



NEVADA LABEL REQUIREMENTS

| | | | |
|-------|--------|-----|--------|
| Δ9THC | 0.261% | CBD | 0.000% |
| THCa | 3.8 % | CBN | 0.000% |

I certify that this sample has been tested by DigiPath Labs. All results are reported on AS-IS basis.
DigiPath Lab Manager Signature: 

A Certificate of Analysis of a chemovar with low THC

The Entourage Effect: Terpenes & Cannabinoids

Terpenoids are essential oil components of cannabis that are very pharmacologically active, even in small concentrations. Cannabinoids are the chemicals found in the cannabis plants. There are hundreds of terpenes and hundreds of cannabinoids that have been found already, as researchers continue to find more. *The entourage effect* is encouraged, especially for medicinal users, because its goal is to include as many cannabinoids and terpenes as possible. There are many more cannabinoids that have medicinal benefits than just THC. For example, the cannabinoid – THCV – and the terpene – Alpha-Pinene – has shown tremendous medicinal benefits.



What Is Alpha-Pinene?

- Alpha-Pinene is an acetylcholine inhibitor, which means it inhibits the enzyme that breaks down acetylcholine, a neurotransmitter in the brain involved with memory
- Alpha-pinene reduces or eliminates the short-term memory impairment produced by THC, and this may be extremely important for medical consumers that need to work or study while they are treating their condition

CHEMOVAR.IO

INCREASE the quality of clinical testing and academic research

Provide a wider range of medical benefits through cannabis

Experienced team dedicated to developing chemovars that can help many patients, especially those experience brain injuries.

What is THCV?

- Tetrahydrocannabivarin, or THCV, is a non-psychoactive cannabinoid
- THCV is considered to increase motivation, increase alertness, and create an energized feeling of euphoria. It is often recommended for daytime or any time when functionality is important
- THCV is known to be neuroprotective. Ideal for treating conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis
- THCV has been shown to have anticonvulsant effects
- THCV decreases the amplitude and duration of abnormal neuronal burst activity
- Unlike THC, THCV works to suppress the appetite so it is not recommended for patients suffering from cachexia or anorexia nervosa

Advancing Clinical Trials

Low THC is generally considered unconventional throughout the cannabis industry. It takes an unconventional team to approach cannabis medicine in a truly holistic way. Eli Addo, from Canalysis, is leading a team which has been researching chemovars that are low in THC but contain other cannabinoids, like THCV. Their research efforts can help academic researchers develop a broader understanding of the cannabis plant. Eli's Team can also help legislators understand what needs to be considered when considering caps on cannabinoid potency.

Contact Eli@canalysis.com for more info